AstraZeneca vaccine: Safety experts to review jab

 

 Vaccine safety experts from the World Health Organization (WHO) are meeting on Tuesday to review the Oxford-AstraZeneca jab, after several European countries halted their rollouts.
A number of cases of blood clots were reported in Europe after the vaccine was administered.
But the numbers are below the level you would expect in the general population.
The UK medicines regulator and the WHO say there is no evidence of a link between the vaccine and clots.
The European Medicines Agency (EMA) - the European Union's medicines regulator - is also meeting on Tuesday.

It is expected to issue its decision on the continued use of the Oxford-AstraZeneca vaccination on Thursday.
About 17 million people in the EU and the UK have received a dose of the vaccine, with fewer than 40 cases of blood clots reported as of last week, AstraZeneca said.
Concerns that there could be a link prompted leading EU states to suspend use of the vaccine, including Germany, France, Italy and Spain.
Other countries, including Austria, have halted the use of certain batches of the drug as a precautionary measure.
However, Belgium, Poland, the Czech Republic and Ukraine said they would continue to administer the AstraZeneca vaccine.
And in Thailand, Prime Minister Prayuth Chan-ocha became the first person in the country to receive the AstraZeneca inoculation.